Ugandan study highlights best drug combinations for treating malaria...( Results of a randomised trial from Ugan...),Health

Results of a randomised trial from Uganda in this week's issue of THE LANCET suggest that the drug combination of amodiaquine and sulfadoxine-pyrimethamine might offer the optimal treatment for malaria in terms of efficacy and cost-effectiveness in this region. The study also shows that the drug combination of chloroquine and sulfadoxine-pyrimethamine--the recommended first-line treatment in Uganda--is far less effective than other drug combinations.

Philip Rosenthal (University of California San Francisco) and colleagues co-ordinated a clinical trial among young children (aged 6 months to 10 years) via a hospital in Kampala, Uganda. Around 400 children were randomly allocated one of three combinations: chloroquine+sulfadoxine-pyrimethamine, amodiaquine+sulfadoxine-pyrimethamine, or amodiaquine+artesunate. The latter two combinations were far more effective, with treatment failures below 10% at one month's follow-up; by contrast, the failure rate of chloroquine+sulfadoxine-pyrimethamine was 35%.

Professor Rosenthal comments: "African countries are faced with a challenge. Escalating drug resistance has rendered chloroquine ineffective, but the best replacement for first-line antimalarial therapy has been unclear. Artemisinin-containing combination therapy has been strongly advocated for use in Africa, but limited clinical experience and the high cost of these regimens are important obstacles. In Kampala, amodiaquine+sulfadoxine-pyrimethamine currently offers a readily available, efficacious, and economical alternativeAlthough the lifespan of amodiaquine+sulfadoxine-pyrimethamine might be limited by resistance, this regimen could be appropriate for regions of Africa where resistance to the individual drugs remains low, as an interim policy pending introduction of artemisinin-containing combinations."

Amir Attaran (University of Ottowa, Canada) states in an accompanying commentary (p 1922): "Rather than clinical efficacy trials, more ur
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
25-Nov-2004

Page: 1 2
Related medicine news :

1. Surprising results for Ugandan HIV intervention trial
2. Reduction in HIV-1 incidence among rural Ugandans gives hope to other African countries
3. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
4. UMaine study looks at infants and chronic nighttime crying
5. Chronic pain treatments more effective when taken together, new study shows
6. UNC study: Most N.C. family practitioners engage in unrecognized community service
7. New study in Nature demonstrates protection against cell death during heart attack
8. UCSF study offers insight into human circadian rhythms
9. International breast cancer prevention study launches in the United States and Canada
10. UW study shows blacks and Latinos are more satisfied with physicians of the same race
11. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study